IP Library Granted Patent US 11,090,454
Granted Patent B2
US 11,090,454 · App. 16/825,848 · Granted Aug 17, 2021

Systems and methods for intelligent gas source management

Inventors: Jaron M. Acker (Madison, WI); Craig R. Tolmie (Stoughton, WI); Robin Roehl (Janesville, WI); Jeffrey Schmidt (Fitchburg, WI); Jeff Milsap (Cambridge, WI)
Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
A61M16/0051A61M16/024A61M16/1005A61M16/12A61M16/122A61M16/125A61M16/201A61M16/202A61M16/204B63C11/02G01F22/02A61M16/085A61M16/208A61M2016/0027A61M2016/0039A61M2016/102A61M2202/0275A61M2205/14A61M2205/16A61M2205/17A61M2205/3331A61M2205/3334A61M2205/3368A61M2205/3379A61M2205/50A61M2205/502A61M2205/52A61M2205/60A61M2205/6018A61M2205/6072A61M2205/8206F17C2250/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,454
App. No.
16/825,848
Granted
Aug 17, 2021
Kind
B2
Abstract

Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system. The therapeutic gas delivery system controller of the system includes a processor that executes an algorithm to calculate the run-time-to-empty from the data received from the gas pressure sensor, temperature sensor, flow controller and flow sensor, and directs the result to the display.

Claims (57)

1. A therapeutic gas delivery system, comprising:

a therapeutic gas source comprising:

a compressed gas cylinder of therapeutic gas; and

at least one gas source identifier containing gas source identifier information, the at least one gas source identifier attached to the compressed gas cylinder and operable to be read by a gas source identifier reader to communicate the gas source identifier information to a therapeutic gas delivery system controller, wherein the gas source identifier information comprises at least one of gas source volume, therapeutic gas identity, therapeutic gas expiration date, and therapeutic gas concentration supplied by the therapeutic gas source; and

at least one gas supply subsystem comprising:

the therapeutic gas delivery system controller comprising a CPU; and

a gas source bay for engagement of the therapeutic gas source in the gas supply subsystem, the gas source bay comprising:

a gas source coupling operable to receive the therapeutic gas source;

a therapeutic gas source detector operatively associated with the gas source coupling, the therapeutic gas source detector operable to detect when the therapeutic gas source is received by the gas source coupling; and

the gas source identifier reader in communication over a communication path with the therapeutic gas delivery system controller, wherein the gas source identifier reader is configured to obtain the gas source identifier information from the gas source identifier when the therapeutic gas source detector detects the therapeutic gas source is properly received by the gas source coupling, and to communicate the gas source identifier information to the therapeutic gas delivery system controller,

wherein the gas source identifier information further includes at least one of, therapeutic gas identity, therapeutic gas expiration date, and therapeutic gas concentration.

2. The therapeutic gas cylinder of claim 1 , wherein the compressed gas cylinder comprises an initial gas pressure of about 2000 psi to about 5000 psi having a therapeutic gas concentration of about 2000 ppm to about 10000 ppm.

3. The therapeutic gas delivery system of claim 1 , wherein the gas source identifier is affixed to an outer surface of the compressed gas cylinder.

4. The therapeutic gas delivery system of claim 1 , wherein the therapeutic gas delivery system controller is configured to compare at least one of the gas source volume, therapeutic gas identity, therapeutic gas concentration, and/or therapeutic gas expiration date to expected values stored in a memory of the therapeutic gas delivery system controller to determine the presence of a correct or incorrect therapeutic gas source.

5. The therapeutic gas delivery system of claim 4 , wherein the therapeutic gas delivery system controller is configured to communicate a signal to a gas source valve on the therapeutic gas source to transition to an open state when the therapeutic gas source is correct.

6. The therapeutic gas delivery system of claim 4 , wherein the therapeutic gas delivery system controller is configured to prompt a user to install a new therapeutic gas source if an incorrect therapeutic gas source is received.

7. The therapeutic gas delivery system of claim 4 , further comprising:

a shutoff valve down stream from the therapeutic gas source, wherein the shutoff valve is operable to be in a closed state until at least one of the gas source volume, therapeutic gas identity, therapeutic gas concentration, and/or therapeutic gas expiration date is verified by the therapeutic gas delivery system controller.

8. The therapeutic gas delivery system of claim 7 , wherein the at least one gas supply subsystem further comprises a purge valve, and after properly receiving the therapeutic gas source, the therapeutic gas delivery system controller is configured to initiate a purge sequence of a conduit between the gas source valve and a closed shutoff valve, wherein the purged gas exits the conduit via the opened purge valve.

9. The therapeutic gas delivery system of claim 4 , further comprising:

a gas pressure sensor operable to measure gas pressure of the therapeutic gas source and communicate the gas pressure to the therapeutic gas delivery system controller.

10. The therapeutic gas delivery system of claim 9 , wherein the therapeutic gas delivery system controller is operable to provide an alarm when the pressure sensor measures a pressure below a minimum threshold.

11. The therapeutic gas delivery system of claim 9 , wherein the therapeutic gas delivery system controller is configured to prompt a user to install a therapeutic gas source if the received therapeutic gas source is determined to be empty and/or the pressure is below the minimum threshold.

12. The therapeutic gas delivery system of claim 1 , wherein the gas source volume is a wetted volume of the gas source.

13. The therapeutic gas delivery system of claim 1 , wherein the therapeutic gas source detector is a micro-switch, a limit switch, or a proximity detector.

14. The therapeutic gas delivery system of claim 1 , wherein the therapeutic gas delivery system controller further comprises memory and the gas source identifier information is communicated to the therapeutic gas delivery system controller and is stored in the memory.

15. The therapeutic gas delivery system of claim 1 , further comprising a display operable to display the gas source identifier information.

16. A method to ensure proper functioning of a therapeutic gas delivery system, the method comprising:

receiving a therapeutic gas source within at least one gas supply subsystem;

reading, via a gas source identifier reader in the at least one gas supply subsystem, gas source identifier information from a gas source identifier attached to the therapeutic gas source, the gas source identifier information providing at least one of gas source volume, therapeutic gas identity, therapeutic gas expiration date, and therapeutic gas concentration;

verifying, via a therapeutic gas delivery system controller in the at least one gas supply subsystem, the gas source identifier information corresponds to an expected therapeutic gas volume, therapeutic gas identity, therapeutic gas concentration, and/or therapeutic gas expiration date;

measuring, via a gas pressure sensor, a gas pressure of the therapeutic gas source;

communicating the gas pressure to the therapeutic gas delivery system controller; and

providing an alarm when the pressure sensor measures below a minimum threshold,

wherein the therapeutic gas delivery system controller prompts a user to install a therapeutic gas source if the received therapeutic gas source is determined to be empty and/or the pressure is below the minimum threshold.

17. The method of claim 16 , wherein the therapeutic gas source is a compressed gas cylinder of therapeutic gas.

18. The method of claim 17 , wherein the gas source identifier is affixed to an outer surface of the compressed gas cylinder.

19. The method of claim 17 , wherein compressed gas cylinder comprises an initial gas pressure of about 2000 psi to about 5000 psi having a therapeutic gas concentration of about 2000 ppm to about 10000 ppm.

20. The method of claim 16 , wherein a shutoff valve down stream from the therapeutic gas source is operable to be in a closed state until a correct identity, concentration, and/or expiration date is verified.

21. The method of claim 16 , wherein the gas source volume is a wetted volume of the gas source.

22. The method of claim 16 , wherein the therapeutic gas delivery system controller comprises memory storing expected volume, identity, concentration, and/or expiration date of the therapeutic gas source, and wherein the gas source identifier information on the gas source identifier is communicated to the therapeutic gas delivery system controller and is stored in the memory, wherein the gas source identifier information further includes at least one of therapeutic gas identity, therapeutic gas concentration and/or therapeutic gas expiration date, wherein the therapeutic gas delivery system controller verifies an expected therapeutic gas identity, therapeutic gas concentration and/or therapeutic gas expiration date.

23. The method of claim 16 , further comprising:

receiving a gas source valve of the therapeutic gas source in a gas source coupling of a gas source bay within the at least one gas supply subsystem; and

detecting, via a therapeutic gas source detector in the at least one gas supply subsystem, when the therapeutic gas source is properly received by the gas source coupling,

wherein the gas source identifier reader obtains the gas source identifier information from the gas source identifier after the therapeutic gas source detector detects the therapeutic gas source is properly received by the gas source coupling.

24. The method of claim 23 , wherein the gas source detector is a micro-switch, a limit switch, or a proximity detector.

25. The method of claim 23 , wherein the therapeutic gas delivery system controller communicates a signal to the gas source valve on the therapeutic gas source to transition to an open state when the therapeutic gas source is correct.

26. The method of claim 23 , wherein the therapeutic gas delivery system controller prompts a user to install a new therapeutic gas source if an incorrect therapeutic gas source is received.

27. A method to ensure proper functioning of a therapeutic gas delivery system, the method comprising:

reading, via a gas source identifier reader in at least one gas supply subsystem, gas source identifier information from a gas source identifier attached to a therapeutic gas source, the gas source identifier information providing at least one of gas source volume, therapeutic gas identity, therapeutic gas expiration date, and therapeutic gas concentration;

verifying, via a therapeutic gas delivery system controller in the at least one gas supply subsystem, the gas source identifier information corresponds to an expected therapeutic gas volume, therapeutic gas identity, therapeutic gas concentration, and/or therapeutic gas expiration date;

initiating, via the therapeutic gas delivery system controller, a purge sequence of a conduit between and a closed shutoff valve after properly receiving the therapeutic gas source; and

opening a purge valve,

wherein the purged gas exits the conduit via the opened purge valve.

28. The therapeutic gas delivery system of claim 1 , wherein the gas source identifier is selected from the group consisting of RFID, a QR code, a bar code, or combinations thereof.

29. The method of claim 16 , wherein the gas source identifier is selected from the group consisting of RFID, a QR code, a bar code, or combinations thereof.

30. The method of claim 27 , wherein the gas source identifier is selected from the group consisting of RFID, a QR code, a bar code, or combinations thereof.

Assignments (13)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED COMPANY
Reel/Frame 075393/0361 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 73375 FRAME 395. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0263 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 72331 FRAME 1. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075021/0204 →
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
CHANGE OF NAME Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 056476/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 056433/0640 →